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cycle regulator, recent work has established a role for pRb in 
Abstract The retinoblastoma susceptibility gene (RB1) is essen- mediating the terminal differentiation f a number of cell types. 
tial for normal embryonic development. Loss of RB1 leads to 
uncontrolled proliferation of a number of cell types but may also 
prevent proper terminal differentiation. The growth-suppressive 2. pRb as a regulator of terminal differentiation 
and differentiation-inducing properties of pRb are impaired by 
cyclin-dependent kinase (cdk)-mediated phosphorylation. Hence, In an attempt o assess the function of pRb in vivo, several 
inhibition of cdk activity is probably a prerequisite for terminal groups have generated mouse strains carrying inactive copies 
differentiation. Indeed, forced cyclin or cdk expression can pre- of the RBI gene [5 7]. Heterozygosity for RB1 does not lead 
vent terminal differentiation in various cell types, probably to an overt developmental phenotype, but homozygous loss of through inhibition of pRb and, possibly, differentiation-specific 
RB1 results in embryonic lethality. Embryos develop normally transcription factors. 
until day 11 of gestation, after which gross abnormalities in
Key words: Retinoblastoma gene product; Differentiation; neurogenesis and erythropoiesis occur, leading to embryonic 
Tumorigenesis; Cyclin-dependent kinase cell death around day 15 [5-7]. The abnormalities occur in 
tissues where expression of the RB1 gene is highest during 
development [8]: in neural tissue and in the fetal liver, the site 
of erythropoiesis at that stage of development. When the de- 
1. Introduction fects in neurogenesis were examined in more detail, it was 
observed that at sites where normally only post-mitotic cells are 
The retinoblastoma susceptibility gene (RB1) is the proto- found, many cells attempt to divide and undergo apoptotic ell 
type tumour suppressor gene. Inactivating mutations in both death [9]. Apparently, loss of pRb leads to uncontrolled prolif- 
alleles are required for the induction of tumorigenesis. In man, eration followed by cell death, resulting in degeneration of the 
germline mutations in one RB1 allele give a predisposition to central and peripheral nervous systems. In addition to uncon- 
retinoblastoma and, to a lesser extent, osteosarcoma. In the trolled proliferation and apoptotic ell death a second phenom- 
resulting turnouts the remaining allele is inactivated indicating enon was observed in Rb / neural tissue: the surviving sensory 
that loss of RB1 is rate-limiting for tumorigenesis (reviewed in neurons are less differentiated than their wild-type counter- 
[l]). Inactivation of RB1 as a result of somatic mutations i also parts, as demonstrated by the lack of expression of neurotro- 
frequently observed in a variety of other tumours. In these phic factor receptors [9]. Signalling through these receptors is 
turnouts loss or Rb function apparently leads to a proliferative normally required for proper terminal differentiation and sur- 
advantage, but is not involved in the initiating step of tumo- rival of neuronal cell types. These observations already suggest 
rigenesis [1]. The observation that re-introduction of wild-type that impaired differentiation is not merely resulting from a 
(wt) RB1 into a number of RBl-negative tumour cell lines failure to arrest he cell cycle, but that pRb also acts to establish 
results in cessation of cell proliferation and loss of tumorigen- terminal differentiation and to ensure cell survival. Indeed, a 
icity, classifies RB1 as a bona fide tumour suppressor gene [1 ] .  number of Rb /- differentiation-committed post-mitotic neu- 
The molecular mechanism by which the RBl-encoded pro- tonal cell types express early differentiation markers, yet fail to 
tein, pRb, inhibits cell growth is becoming increasingly clear, mature into fully differentiated neurons [9,10]. Second, Rb /- 
pRb binds to and inhibits the action of various proteins, includ- lens fibre cells express early, but not late differentiation mark- 
ing the ubiquitously expressed tyrosine kinase c-Abl, the T-cell- ers, suggesting a function for pRb during more advanced stages 
specific transcription factor Elf-1 and members of the E2F of the differentiation process [12]. In addition to neuronal dis- 
family of transcription factors [24]. These proteins function by orders, Rb /- embryo's uffer from impaired erythrocyte differ- 
stimulating progression through S-phase. Cell cycle-dependent entiation [5 7]. However, studies on the phenotype ofchimaeric 
phosphorylation f pRb by cdk's releases these proteins from Rb+/+/Rb /- mice showed that this was an indirect effect of liver 
pRb-imposed inhibition and ensures proper timing of their malfunction, and that pRb is not essential for terminal differen- 
activities [2-4]. Thus, pRb inhibits cell growth by preventing tiation of erythrocytes a  such, but may be required for proper 
initiation of the S-phase. In addition to its function as a cell functioning of hepatocytes [10,11]. 
The chimaeric Rb*/+/Rb -/- mice developed normally, even 
though the contribution of Rb /- cells to all tissues examined, 
*Corresponding author, Fax: (31) (71 ) 276284. including neural tissue, was considerable [ 10,11 ]. This suggested 
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that loss of RB1 is largely rescued by the presence of wt cells, Rb-/- 
suggesting that pRb is not required cell-autonomously. How- n ° ~ ]  / j / ] 
ever, the fact that enhanced levels of cell death were found in 
I 1.rescue (p107/D130) the spinal ganglia, the retina, and the eye lens of the chimaeric 12.pRb digpensh'ble 
animals [10-12], suggests that selection for Rb ÷/+ cells is taking ] 
place in these tissues. Indeed, the retina of the chimaeric ani- cell cycle arrest: I ] yes ] 
mals consisted mainly of Rb +/+ cells [11]. Thus, pRb is required 
cell-autonomously in a restricted number of cell types. The P~ ~ ] ] impaired 
neuronal (Rb -/-) cell types that were not affected in the differentiation 
chimaeric animals may be rescued by the presence of neigh- I 
bouring Rb +/+ cells. Although the existence of such a trans- 
acting rescue mechanism has not been proven, it may involve tissue: degeneration proliferation malfunction normal 
secretion of signalling proteins with differentiation-inducing Fig. 1. Effects of RBl-loss on cell proliferation and differentiation. 
properties. The molecular mechanism through which pRb me- Homozygous loss of RB1 has different effects on different cell types. 
diates terminal differentiation remains to be elucidated and is In a number of cell types loss of pRb leads to loss of cell cycle control, 
possibly cell type dependent, followed by p53-induced programmed cell death (PCD), resulting in 
In summary, loss of Rb function has, either directly or indi- tissue degeneration. I  cells where uncontrolled proliferation does not 
lead to PCD, initiation of tumorigenesis can occur. Alternatively, loss 
rectly, profound effects on the terminal differentiation of vari- of pRb may contribute to, but not be sufficient for, the initiation of 
ous cell types in vivo. tumorigenesis. Loss of cell cycle control may also be rescued by pRb- 
In vitro studies on the terminal differentiation of myoblasts related proteins, ensuring cell cycle arrest. In some cell types where pRb 
into myotubes have implicated pRb in the regulation of this is not required for cell cycle arrest, or where its function is rescued, loss 
of pRb may affect he ability of cells to undergo terminal differentia- 
process [13]. Underphosphorylated pRb mediates the forma- tion, possibly resulting in tissue malfunction. See text for details and 
tion of a heterodimeric transcription factor composed of MyoD references. 
(or its relatives myogenin or Myf5) and E2 [13]. This transcrip- 
tion factor complex drives muscle-specific gene expression and 
its activation is sufficient o convert some non-myogenic cell 
types into myogenic ell types [14]. In terminally differentiated tissues and the characterisation f pRb as a constrainer of cell 
myotubes pRb is underphosphorylated an  thus constitutively growth seems contradictory to the limited range of tumour 
active as a growth suppressor and as an inducer of myogenic types that is directly correlated with loss of its function. A 
gene expression. Why then, if pRb is so important in the regu- simple explanation could be that, although present in many cell 
lation of this process, do the Rb -/- embryos not display any types, pRb is not required for cell cycle control in most of these 
muscular abnormalities? The answer to this question has re- cell types and loss of its function will thus remain without effect. 
cently been provided: pRb belongs to a (still small) family of Alternatively, in certain cell types loss of RB1 may contribute 
proteins with growth suppressing properties, the other family to tumorigenesis, but additional genetic changes may be re- 
members being p107 and p130. When p107 was tested for its quired for the initiation of tumour growth. Another possibility 
ability to activate MyoD-dependent gene expression, it ap- is that p107 or p130 may substitute for pRb as growth suppres- 
peared that it is as capable as pRb in performing this task [15]. sors. Although aberrations in the chromosomal region har- 
In addition, when Rb -/- myoblasts are stimulated to differenti- bouring the p107 gene are not observed in common forms of 
ate, an increase ofpl07 expression is seen in the Rb -/- but not cancer [16], the region harbouring the p130 gene is lost in 
in the wt cells, strongly suggesting that p 107 substitutes for pRb several tumour types [17]. Finally, in Rb -/- mice, degeneration 
in the regulation of terminal myogenic differentiation [15]. of a number of tissues was observed, apparently due to apop- 
However, it also implies that the function of pRb may be much totic cell death [5-7], suggesting that in these cell types tumo- 
more pleiotropic than the phenotype of the Rb -/- mice would rigenesis is prevented by activation of the apoptotic pathway. 
suggest. Both p107 or p130, or even other unidentified family Recent studies have implicated p53, another tumour suppressor 
members, may substitute for pRb in the regulation of differen- protein, in this process. In a p53 nullizygous background the 
tiation or other processes, thereby masking the fact that nor- tumour-take in response to heterozygous loss of RB1 is greatly 
really pRb would mediate these processes, enhanced [18]. Furthermore, inactivation of pRb and its family 
members by targeted expression of viral oncogenes in specific 
3. pRb as a tumour suppressor cell types (including retina cells) results in apoptotic ell death 
and slow or no tumour growth in the presence of p53. However, 
Mice heterozygous for RB1 develop normally but are predis- in the absence of functional p53, loss of RB1 leads to uncon- 
posed to pituitary tumours, rather than retinoblastomas trolled proliferation i  these cells [12,19~2]. Thus, in a number 
[5,6,10,11]. In the pituitary tumours the remaining wt allele is of cell types, including retinoblasts, tumorigenesis a a result of 
lost. This, together with the observation that chimaeric Rb+/+/ loss of RB1, is prevented by the activation of a p53-mediated 
Rb + mice develop ituitary tumours at much earlier age than mechanism that leads to apoptotic ell death. Although these 
the Rb +/- mice [10,11], suggests that loss of RB1 is a rate- studies provide an explanation for the fact that Rb +/- mice are 
limiting step in the genesis of pituitary tumours in the mouse, not predisposed to retinoblastoma [12,21,22], the question re- 
as it is for retinoblastomas in man. The control of cell cycle mains why human retina cells and mouse pituitary cells are 
progression i these cell types is thus largely dependent on pRb, sensitive to the loss of pRb function, as consecutive loss of p53 
and loss of its function is apparently sufficient o initiate tu- is rarely observed in these tumours [1,18]. In Fig. 1 the possible 
morigenesis. The ubiquitous expression pattern of RB1 in adult fates of cell types having lost RB1 is schematically outlined. 
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differentiation signal growth facxors suppression by MyoD, even in non-convertable c ll types. In 
J_p R addition, the expression of p21 clPl during myogenesis n vivo 
21,~ , ~ coincides with that ofmyogenin, suggesting that myogenin may 
be the physiological regulator of p21 clP1 expression during 
I [ my°genesis [34]" It has even been suggested that p21Clpl °verex- 
cyclin/cdk pression may be sufficient o induce myogenesis n vitro, al- 
though this process seemed to require contact-inhibition [36]. 
~P21'~' 1 Another CKI, p27 Kw~ has been reported to be activated in 
response to contact-inhibition [37], so may help to establish 
DS-TF/pRb - '~  DR terminal differentiation. 
PP-I b When terminally differentiated myotubes are stimulated with 
growth factors, pRb phosphorylation does not occur and cells 
do not synthesize DNA. Thus, terminally differentiated cells 
cell cycle arrest I proliferation[ 
differentiation are locked in a state in which they are non-responsive to growth 
factor stimulation. The presence of high levels of CKI's, inhib- 
Fig. 2. Control on cdk activity during the proliferation-differentiation iting cdk activity and pRb phosphorylation, may (partly) ex- 
switch. The model is based on reports describing terminal myogenic plain why terminally differentiated cells are refratory to growth 
differentiation a d is hypothetically generalised. In response to a differ- factor stimulation. 
entiation signal, CKI-expression (possibly p21 c~p~) is stimulated, result- In another approach to studying the importance of cdk reg- ing in an inhibition of cdk activity. With this, the inhibitory 
phosphorylations onpRb and differentiation-specific transcription fac- ulation during differentiation, various groups have investigated 
tors (DS-TF) are lost. As a result pRb arrests the cell cycle and, in the effects of cyclin or cdk overexpression  the commitment 
conjunction with the DS-TF, helps establishing the genetic program of a cell to undergo terminal differentiation [27-29]. In response 
leading to terminal differentiation. The DS-TF locks cells in a growth to a differentiation signal, mouse myeloid precursor cells over- 
factor non-responsive state by stimulating expression of the genes en- 
coding p21 cwl and pRb. Possibly, additional pathways (DS-TF's) are expressing either cyclin D2 or D3 do not differentiate but die 
activated in response to the differentiation signal to ensure terminal [28]. Overexpression f the cyclin D-dependent kinase cdk4, but 
differentiation, not cdk2 inhibits erythroid ifferentiation i vitro [29]. As pRb 
function is not required for erythroid ifferentiation i  vivo (see 
above) a cdk4-mediated ffect other than pRb phosphorylation 
presumably underlies this phenomenon. Evidence that cyclin 
4. G1 cdk's as regulators of the proliferation-differentiation D-dependent kinases indeed control the activity of additional 
switch regulatory proteins was recently presented: in myoblasts, cyclin 
D-dependent kinase activity was found to prevent MyoD-de- 
Several years ago it was observed that phosphorylation of pendent promoter activation [27,36]. This effect is a result of 
pRb is lost during terminal differentiation of various cell lines cyclin D 1-mediated MyoD-phosphorylation, resulting in its in- 
in vitro [23,24]. Moreover, underphosphorylated pRb accumu- activation. Moreover, specific inhibition of cyclin D-dependent 
lates in terminally differentiated neurons [9,25]. Specifically the kinase activity by overexpression f the CKI p16 ~NK4 stimulates 
underphosphorylated form of pRb binds to c-Abl, Elf-l, E2F's MyoD-dependent promoter activation, indicating that cyclin 
and MyoD, implying that inhibition of pRb phosphorylation D-dependent kinases may serve to keep the differentiation pro- 
will activate both its growth suppressive and (myogenic) differ- gram silent by inactivating both pRb and differentiation-induc- 
entiation-inducing potential. As mentioned in the introduction, ing transcription factors [36]. It is tempting to extrapolate these 
cyclin-dependent kinases are believed to function as pRb ki- findings and to also postulate the existence of master class 
nases. Of the cyclin-cdk complexes, cyclin D-cdk4/6 and cyclin transcription factors for other differentiation routes, being 
E-cdk2 presumably cooperate to induce hyperphosphorylation prone to negative regulation by cyclin (D)-dependent kinases 
of pRb during late G 1, prior to the onset of DNA synthesis [2]. (Fig. 2). In this respect, it must be noted that although all three 
Therefore, it seems likely that inhibition of cdk activity is a D-type cyclins activate cdk4 and cdk6 there are major differ- 
prerequisite for the switch from proliferation to differentiation ences with respect to both their expression patterns [38,39] and 
to occur. Multiple levels of regulation determine the activity of functional performances [27,28,36,40,41]. For instance, the 
a cdk [26]. Activation requires association to a cyclin partner abundance of cyclin D3, but not D 1 or D2, is increased uring 
and phosphorylation f the kinase itself. Inhibition of cdk ac- both terminal myogenic [30,36] and erythroid [29] differentia- 
tivity also involves phosphorylation a d, in addition, associa- tion. During these processes cyclin D3 accumulates in inactive 
tion to cdk-inhibitors (CKI's). During various terminal differ- kinase complexes with unknown (if any) functional conse- 
entiation pathways, the expression of both cyclin as well as cdk quences. In addition, cyclins D2 and D3 can activate cdk2 
subunits were shown to be prone to downregulation, precluding whereas cyclin D 1 can not [41]. Conversely, a mutant form of 
the formation of active cyclin/ckd complexes [27 30]. In addi- cyclin D1 that is unable to bind pRb is more effective in reliev- 
tion, enhanced expression of the CKI p21 c~pj has recently been ing pRb-induced cell cycle arrest than wt cyclin D 1, whereas 
observed in a number of differentiation pathways [31 34]. Dur- a similar D2 mutant is ineffective [40,41]. Given these differ- 
ing embryonic development, the highest levels of p21 clpt ex- ences it is impossible to assign a universal function to the 
pression are confined to post-mitotic ells of various origins D-type cyclins in differentiation or cell cycle control. 
[34]. During terminal myogenic differentiation the genes encod- An effect of cyclin E overexpression  terminal differentia- 
ing p21 c~p~ and pRb are direct argets for transcriptional ctiva- tion has not been reported. It seems likely however, that, if 
tion by MyoD [33,35], presenting an explanation for growth possible to achieve, artificially sustained cyclinE-cdk2 activity 
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would suffice to prevent pRb-dependent terminal differentia- [17] Li, Y., Graham, C., Lacy, S., Duncan, A.M.V. and Whyte, P. 
tion. (1993) Genes Dev. 7, 2366-2377. 
In summary, the switch from proliferation to differentiation [18] Williams, B.O., Remington, L., Albert, D.M., Mukai, S., Bronson, 
R.T. and Jacks, T. (1994) Nature Genet. 7, 480~484. 
involves inactivation of cdk activity. As a result phosphoryla- [19] White, E. (1994) Nature 371, 21 22. 
tion of pRb is lost, leading to activation of its function as a [20] Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, 
growth suppressor and inducer of differentiation. Additionally, S., Jacks, T. and van Dyke, T. (1994) Cell 78, 703 711. 
the loss ofcdk activity may lead to activation of differentiation- [21] Howes, K.A., Ransom, N., Papermaster, D.S., Lasudry, J.G.H., 
Albert, D.M. and Windle, J.J. (1994) Genes Dev. 8, 1300- 
specific transcription factors. 1310. 
[22] Pan, H. and Griep, A.E. (1994) Genes Dev. 8, 1285-1299. 
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